Key result
Higher plasma total homocysteine levels were significantly associated with unfavorable 3-month functional outcomes in patients with AF-related stroke (OR 1.04; 95% CI 1.01-1.07 per 1 μmol/L).
Why the study?
The prognostic effect of elevated plasma total homocysteine in patients with both ischemic stroke and atrial fibrillation was unknown.
Is elevated plasma total homocysteine associated with unfavorable outcomes in patients with atrial fibrillation-related ischemic stroke?
Cohort (n=910)
Yes
Is elevated plasma total homocysteine associated with unfavorable outcomes in patients with atrial fibrillation-related ischemic stroke?
Odds Ratio: 1.04 (95% CI 1.01–1.07)
Elevated plasma total homocysteine is an independent predictor of unfavorable functional outcomes at 3 months in patients with AF-related ischemic stroke, particularly those with normal renal function.
May refine prognostication in AF-related stroke; hypothesis-generating for targeted interventions.
Background Unlike patients with stroke caused by other mechanisms, the effect of elevated plasma total homocysteine (tHcy) on the prognosis of patients with both ischemic stroke and atrial fibrillation (AF) is unknown. This study aimed to evaluate the association between tHcy level and the functional outcome of patients with AF-related stroke. Methods and Results We included consecutive patients with AF-related stroke between 2013 and 2015 from the registry of a real-world prospective cohort from 11 large centers in South Korea. A 3-month modified Rankin Scale score ≥3 was considered an unfavorable outcome. Since tHcy is strongly affected by renal function, we performed a subgroup analysis according to the presence of renal dysfunction. A total of 910 patients with AF-related stroke were evaluated (mean age, 73 years; male sex, 56.0%). The mean tHcy level was 11.98±8.81 μmol/L. In multivariable analysis, the tHcy level (adjusted odds ratio, 1.04; 95% CI, 1.01-1.07, per 1 μmol/L) remained significantly associated with unfavorable outcomes. In the subgroup analysis based on renal function, tHcy values above the cutoff point (≥14.60 μmol/L) showed a close association with the unfavorable outcome only in the normal renal function group (adjusted odds ratio, 3.10; 95% CI, 1.60-6.01). In patients with renal dysfunction, tHcy was not significantly associated with the prognosis of AF-related stroke. Conclusions A higher plasma tHcy level was associated with unfavorable outcomes in patients with AF-related stroke. This positive association may vary according to renal function but needs to be verified in further studies.
No takes yet. Share an insight, caveat, or question.
A 2022 study conducted a cohort in Ischemic stroke with atrial fibrillation (n=910). Plasma total homocysteine (tHcy) level vs. Lower tHcy levels was evaluated on Unfavorable outcome (3-month modified Rankin Scale score ≥3) (OR 1.04, 95% CI 1.01-1.07). Higher plasma total homocysteine levels were significantly associated with unfavorable 3-month functional outcomes in patients with AF-related stroke (OR 1.04; 95% CI 1.01-1.07 per 1 μmol/L).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: